29 related articles for article (PubMed ID: 2334125)
1. Prolactin inducible protein in cancer, fertility and immunoregulation: structure, function and its clinical implications.
Hassan MI; Waheed A; Yadav S; Singh TP; Ahmad F
Cell Mol Life Sci; 2009 Feb; 66(3):447-59. PubMed ID: 18854942
[TBL] [Abstract][Full Text] [Related]
2. Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells.
Lin CY; Ström A; Vega VB; Kong SL; Yeo AL; Thomsen JS; Chan WC; Doray B; Bangarusamy DK; Ramasamy A; Vergara LA; Tang S; Chong A; Bajic VB; Miller LD; Gustafsson JA; Liu ET
Genome Biol; 2004; 5(9):R66. PubMed ID: 15345050
[TBL] [Abstract][Full Text] [Related]
3. The mouse one P-domain (pS2) and two P-domain (mSP) genes exhibit distinct patterns of expression.
Lefebvre O; Wolf C; Kédinger M; Chenard MP; Tomasetto C; Chambon P; Rio MC
J Cell Biol; 1993 Jul; 122(1):191-8. PubMed ID: 8314841
[TBL] [Abstract][Full Text] [Related]
4. pS2 and response to adjuvant hormone therapy in primary breast cancer.
Spyratos F; Andrieu C; Hacène K; Chambon P; Rio MC
Br J Cancer; 1994 Feb; 69(2):394-7. PubMed ID: 8297741
[TBL] [Abstract][Full Text] [Related]
5. Detection of estradiol-induced messenger RNA (pS2) in uninvolved breast tissue from mastectomies for breast cancer.
Hähnel E; Joyce R; Sterrett G; Harvey J; Hähnel R
Breast Cancer Res Treat; 1992 Mar; 20(3):167-76. PubMed ID: 1571569
[TBL] [Abstract][Full Text] [Related]
6. The pS2 gene, mRNA, and protein: a potential marker for human breast cancer.
Rio MC; Chambon P
Cancer Cells; 1990; 2(8-9):269-74. PubMed ID: 2223388
[TBL] [Abstract][Full Text] [Related]
7. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer.
Daffada AA; Johnston SR; Smith IE; Detre S; King N; Dowsett M
Cancer Res; 1995 Jan; 55(2):288-93. PubMed ID: 7812959
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of the cytosolic content of the pS2 protein in breast cancer].
Tamargo F; Vizoso F; Lamelas ML; Rodil A; Vérez P; Raigoso P; Mulero M; Vázquez J; Roiz C; Allende MT
Rev Esp Med Nucl; 2002 Feb; 21(1):28-33. PubMed ID: 11820999
[TBL] [Abstract][Full Text] [Related]
9. Interactions between estrogens, androgens, progestins, and glucocorticoids in ZR-75-1 human breast cancer cells.
Labrie F; Poulin R; Simard J; Zhao HF; Labrie C; Dauvois S; Dumont M; Hatton AC; Poirier D; Mérand Y
Ann N Y Acad Sci; 1990; 595():130-48. PubMed ID: 2142871
[TBL] [Abstract][Full Text] [Related]
10. The potential role for prolactin-inducible protein (PIP) as a marker of human breast cancer micrometastasis.
Clark JW; Snell L; Shiu RP; Orr FW; Maitre N; Vary CP; Cole DJ; Watson PH
Br J Cancer; 1999 Nov; 81(6):1002-8. PubMed ID: 10576657
[TBL] [Abstract][Full Text] [Related]
11. Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors.
Marsigliante S; Biscozzo L; Correale M; Paradiso A; Leo G; Abbate I; Dragone CD; Storelli C
Br J Cancer; 1994 Mar; 69(3):550-4. PubMed ID: 8123486
[TBL] [Abstract][Full Text] [Related]
12. Hormone-sensitive gene expression in breast tumours.
Wysocki SJ; Hahnel E; Wilkinson SP; Smith V; Hahnel R
Anticancer Res; 1990; 10(1):185-8. PubMed ID: 2334125
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of the estrogen regulated pS2 protein in mammary tumors.
Pichon MF; Milgrom E
Crit Rev Oncol Hematol; 1993 Aug; 15(1):13-21. PubMed ID: 8240704
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
